Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Other Non-Current Receivables (Details)

v3.21.1
Other Non-Current Receivables (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Sep. 10, 2019
USD ($)
shares
Feb. 17, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
shares
Other Non-Current Receivables (Details) [Line Items]        
Number of instalments payment 2      
Univo Pharmaceuticals [Member]        
Other Non-Current Receivables (Details) [Line Items]        
Amount agreed to pay by company $ 500      
Number of ordinary shares issued (in Shares) | shares       19,934,355
Number of indications   2    
Fund paid per indication   $ 200    
Laboratory services expenses     $ 2,199 $ 201
Univo Pharmaceuticals [Member] | Private Placement [Member]        
Other Non-Current Receivables (Details) [Line Items]        
Number of ordinary shares issued (in Shares) | shares 19,934,355      
Percentage of outstanding shares 16.60%